44.42
전일 마감가:
$45.49
열려 있는:
$45.56
하루 거래량:
1.44M
Relative Volume:
0.67
시가총액:
$5.50B
수익:
$692.26M
순이익/손실:
$-512.41M
주가수익비율:
-10.48
EPS:
-4.24
순현금흐름:
$-274.36M
1주 성능:
-4.39%
1개월 성능:
-10.98%
6개월 성능:
-5.91%
1년 성능:
+39.12%
가든트헬스 Stock (GH) Company Profile
명칭
Guardant Health Inc
전화
855-698-8887
주소
3100 HANOVER STREET, PALO ALTO
GH을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
GH
Guardant Health Inc
|
44.42 | 5.64B | 692.26M | -512.41M | -274.36M | -4.24 |
![]()
TMO
Thermo Fisher Scientific Inc
|
478.32 | 179.32B | 43.21B | 6.58B | 6.17B | 17.29 |
![]()
DHR
Danaher Corp
|
205.48 | 145.22B | 24.01B | 3.41B | 4.86B | 4.70 |
![]()
IDXX
Idexx Laboratories Inc
|
565.19 | 44.23B | 3.93B | 894.97M | 837.70M | 10.82 |
![]()
IQV
Iqvia Holdings Inc
|
199.17 | 34.14B | 15.50B | 1.33B | 2.16B | 7.34 |
![]()
A
Agilent Technologies Inc
|
120.18 | 34.19B | 6.63B | 1.17B | 1.19B | 4.05 |
가든트헬스 Stock (GH) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-10 | 개시 | Mizuho | Outperform |
2025-01-23 | 개시 | Barclays | Overweight |
2024-06-28 | 업그레이드 | Guggenheim | Neutral → Buy |
2024-06-03 | 재개 | Jefferies | Buy |
2024-04-24 | 재개 | Craig Hallum | Buy |
2023-12-14 | 개시 | Guggenheim | Neutral |
2023-12-13 | 개시 | Wolfe Research | Peer Perform |
2023-11-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2023-09-28 | 개시 | Bernstein | Outperform |
2023-09-27 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2023-07-05 | 재개 | JP Morgan | Overweight |
2023-05-26 | 업그레이드 | Citigroup | Neutral → Buy |
2023-05-05 | 개시 | UBS | Buy |
2023-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
2023-01-05 | 개시 | Scotiabank | Sector Outperform |
2022-11-01 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2022-10-19 | 개시 | Craig Hallum | Buy |
2022-10-06 | 개시 | Stephens | Overweight |
2022-08-25 | 개시 | Credit Suisse | Outperform |
2022-06-03 | 개시 | Piper Sandler | Overweight |
2022-04-28 | 재개 | BTIG Research | Buy |
2022-02-24 | 재확인 | Canaccord Genuity | Buy |
2022-02-24 | 재확인 | Citigroup | Buy |
2022-02-24 | 재확인 | Cowen | Outperform |
2022-02-24 | 재확인 | Morgan Stanley | Overweight |
2022-02-24 | 재확인 | SVB Leerink | Outperform |
2022-02-24 | 재확인 | Stifel | Buy |
2022-02-24 | 재확인 | Wells Fargo | Overweight |
2021-10-15 | 재개 | Cowen | Outperform |
2021-06-15 | 개시 | Raymond James | Mkt Perform |
2021-06-03 | 개시 | Goldman | Buy |
2021-05-25 | 개시 | Wells Fargo | Overweight |
2021-01-11 | 개시 | Stifel | Buy |
2020-09-09 | 개시 | Morgan Stanley | Overweight |
2020-06-12 | 개시 | BTIG Research | Buy |
2020-02-21 | 개시 | Guggenheim | Buy |
2020-01-07 | 개시 | Citigroup | Buy |
2019-08-07 | 재확인 | Canaccord Genuity | Buy |
2019-04-16 | 개시 | Canaccord Genuity | Buy |
2019-04-10 | 업그레이드 | BofA/Merrill | Neutral → Buy |
2019-02-28 | 재확인 | BofA/Merrill | Neutral |
2018-10-29 | 개시 | BofA/Merrill | Neutral |
2018-10-29 | 개시 | JP Morgan | Overweight |
2018-10-29 | 개시 | William Blair | Outperform |
모두보기
가든트헬스 주식(GH)의 최신 뉴스
What institutional investors are buying Guardant Health Inc. stockUnprecedented market success - jammulinksnews.com
What catalysts could drive Guardant Health Inc. stock higher in 2025Lightning-fast growth - jammulinksnews.com
What are Guardant Health Inc. company’s key revenue driversCapitalize on emerging market sectors - jammulinksnews.com
What are the latest earnings results for Guardant Health Inc.Maximize returns with timely market signals - jammulinksnews.com
What makes Guardant Health Inc. stock price move sharplyCapital Safe Stock Watchlist - Metal.it
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics - Benzinga
Guardant Health Enrolls First Patient in NCI Vanguard Study for Multi-Cancer Detection Test - MSN
What drives Guardant Health Inc. stock priceConsistent wealth multiplication - PrintWeekIndia
Minimal Residual Disease Testing Market Trends Analysis Report 2025-2030 | North America Leads in MRD Testing Market with Advanced Reimbursement Ecosystem - GlobeNewswire Inc.
Is Guardant Health Inc. a good long term investmentDynamic growth stocks - PrintWeekIndia
1 Healthcare Stock with Solid Fundamentals and 2 We Avoid - Yahoo Finance
What analysts say about Guardant Health Inc. stockFree Stock Selection - Autocar Professional
10 Best Mid Cap Pharma Stocks to Buy - Insider Monkey
Colonoscopies are no fun. These at-home colon cancer screenings offer a shortcut. - Business Insider
Guardant Health (NASDAQ:GH investor five-year losses grow to 44% as the stock sheds US$228m this past week - Yahoo Finance
Guardant Health Inc. Stock Analysis and ForecastFree Capital Allocation Plans - jammulinksnews.com
3 Reasons to Avoid GH and 1 Stock to Buy Instead - Yahoo Finance
Cathie Wood’s ARK ETFs shift focus, buying NVIDIA and selling GUARDANT - Investing.com
Freenome's new CEO is ready to compete in race for tests that can detect cancer early - The Business Journals
Cathie Wood's Ark Invest Offloads Meta, Loads Up On Teradyne, Caris Life Sciences - Benzinga
Guardant Health (GH): director Tariq Musa sells $5591 in stock By Investing.com - Investing.com South Africa
Guardant Health (GH): director Tariq Musa sells $5591 in stock - Investing.com
Guardant Health Director Sells 142 Shares at $48.2 Per Share on 2025-07-17. - AInvest
Global Liquid Biopsy Market Size Worth USD 25.24 Billion By 2032 | - openPR.com
Lung Cancer Diagnostics Market Expansion Driven by Liquid - openPR.com
(GH) Technical Data - news.stocktradersdaily.com
User - FinancialContent
Evercore ISI Keeps Their Buy Rating on Guardant Health (GH) - The Globe and Mail
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test - Yahoo Finance
Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025 - BioSpace
Guardant Health stock price target maintained at $60 by Evercore ISI - Investing.com Canada
Press Release: Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025 - 富途牛牛
가든트헬스 (GH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):